Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celularity Inc (CELU)

Celularity Inc (CELU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,624
  • Shares Outstanding, K 28,838
  • Annual Sales, $ 54,220 K
  • Annual Income, $ -57,890 K
  • EBIT $ -47 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.70
  • Price/Sales 0.75
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 225.56% (+3.31%)
  • Historical Volatility 64.50%
  • IV Percentile 66%
  • IV Rank 16.60%
  • IV High 900.41% on 12/23/25
  • IV Low 91.28% on 09/08/25
  • Expected Move (DTE 4) 0.0085 (0.67%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 544
  • Open Int (30-Day) 544
  • Expected Range 1.2615 to 1.2785

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.20
  • Growth Rate Est. (year over year) +45,509.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1550 +9.96%
on 03/26/26
1.4500 -12.41%
on 04/08/26
-0.1200 (-8.63%)
since 03/10/26
3-Month
1.0701 +18.68%
on 03/03/26
1.5100 -15.89%
on 02/18/26
-0.0300 (-2.31%)
since 01/09/26
52-Week
1.0100 +25.74%
on 12/31/25
4.3500 -70.80%
on 07/22/25
-0.2300 (-15.33%)
since 04/10/25

Most Recent Stories

More News
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  ...

CELU : 1.2700 (-6.62%)
NXGL : 0.5721 (-7.74%)
NXGLW : 0.0540 (+34.66%)
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline...

CELU : 1.2700 (-6.62%)
NXGL : 0.5721 (-7.74%)
CELUW : 0.0078 (-11.36%)
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified...

CELU : 1.2700 (-6.62%)
NXGL : 0.5721 (-7.74%)
NXGLW : 0.0540 (+34.66%)
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Transaction expected to generate up to $35 million in upfront and milestone payments Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunity ...

CELU : 1.2700 (-6.62%)
CELUW : 0.0078 (-11.36%)
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2...

CELU : 1.2700 (-6.62%)
CELUW : 0.0078 (-11.36%)
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,...

CELU : 1.2700 (-6.62%)
CELUW : 0.0078 (-11.36%)
Celularity Announces Closing of Financing Transactions

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,...

CELU : 1.2700 (-6.62%)
CELUW : 0.0078 (-11.36%)
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance. FLORHAM PARK,...

CELU : 1.2700 (-6.62%)
CELUW : 0.0078 (-11.36%)
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,...

CELU : 1.2700 (-6.62%)
CELUW : 0.0078 (-11.36%)
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease Celularity PDA-002 achieved durable wound healing with just two intramuscular doses As a qualified...

CELU : 1.2700 (-6.62%)
CELUW : 0.0078 (-11.36%)

Business Summary

Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells...

See More

Key Turning Points

3rd Resistance Point 1.4450
2nd Resistance Point 1.4100
1st Resistance Point 1.3400
Last Price 1.2700
1st Support Level 1.2350
2nd Support Level 1.2000
3rd Support Level 1.1300

See More

52-Week High 4.3500
Fibonacci 61.8% 3.0741
Fibonacci 50% 2.6800
Fibonacci 38.2% 2.2859
Last Price 1.2700
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.